Results: The case was coordinated between the out-patient psychiatry department and the patient’s Family Medicine specialist. The patient underwent a complete panel of tests including blood and stool test, and colonoscopy. The biopsy showed results compatible with the aforementioned diagnosis. Since the only pharmacological treatment which could cause or trigger lymphocytic colitis was sertraline, it was removed and treatment with oral budesonide was started with good results.

Conclusions: Lymphocytic colitis in the context of the treatment with SSRIs, particularly sertraline, is a side-effect which is more prevalent than what was thought in the past. A close coordination between psychiatrists and GP is of vital importance for the adequate treatment of mental health problems and treatment’s side-effects. It is important to bear in mind this possible side-effect to increase patient’s safety.

Disclosure: No significant relationships.

Keywords: lymphocytic colitis; side-effect; sertraline

EPV1157

A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N,N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers

J. Reckweg1, N. Mason1, C. Van Leeuwen2, S. Tönnes2, T. Terwey3 and J. Ramaekers1

1Maastricht University, Faculty Of Psychology And Neuroscience, Department Of Neuropsychology And Psychopharmacology, Maastricht, Netherlands; 2Goethe-Universität Frankfurt am Main, Institut Für Rechtsmedizin, Frankfurt am Main, Germany; 3GH Research PLC, Chief Executive Officer, Dublin, Ireland

Introduction: 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) is a tryptamine with ultra-rapid onset and short duration of psychedelic effects. Prospective studies for other tryptamines have suggested beneficial effects on mental health outcomes.

Objectives: In preparation for a study in patients with depression, the present study GH001-HV-101 aimed to assess the impact of four different dose levels of a novel vaporized 5-MeO-DMT formulation (GH001) administered via inhalation as single doses, and in an individualized dose escalation regimen on the safety, tolerability, and the dose-related psychoactive effects in healthy volunteers (n=22). Further, we aimed to assess the impact on cognitive functioning, mood, and well-being.

Methods: The psychedelic experience was assessed with a novel Peak Experience Scale (PES), the Mystical Experience Questionnaire (MEQ), the Ego Dissolution Inventory (EDI), the Challenging Experience Questionnaire (CEQ), and the 5-Dimensional Altered States of Consciousness Questionnaire (5D-ASC).

Results: 5-MeO-DMT produced dose-related increments in the intensity of the psychedelic experience ratings on all questionnaires, except the CEQ. Prominent effects were observed following single doses of 6, 12, and 18 mg on PES and MEQ ratings, while maximal effects on PES, MEQ, EDI, and 5D-ASC ratings were observed following individualized dose escalation of 5-MeO-DMT. Measures of cognition, mood, and well-being were not affected. Vital signs at 1 and 3 h after administration were not affected and adverse events were generally mild and resolved spontaneously.

Conclusions: Individualized dose escalation of 5-MeO-DMT may be preferable over single dose administration for clinical applications that aim to enhance the short-term psychoactive effects to elicit a strong therapeutic response.

Disclosure: This study was funded by GH Research PLC, Dublin, Ireland.

Keywords: GH001; 5-MeO-DMT; Phase 1; Safety

EPV1159

Nitrous Oxide in Treatment Resistant Major Depression: Should We Laugh About It?

B. Leal1*, D. Vila-Chá, S. Garcia, I. Pinto, R. Mateiro, M. Avelino, M. Martins and J. Salgado

Centro Hospitalar Psiquiátrico de Lisboa, Clínica 1, Lisboa, Portugal

*Corresponding author.
doi: 10.1192/j.eurpsy.2022.1847

Introduction: Nitrous oxide (NO), also known as “laughing gas” is a colorless gas used as an anesthetic, a propellant in some foods, an engine performance enhancer and a recreational drug. When inhaled, it is known to provoke a rapid feeling of euphoria or excitement for a short period of time, dissociative phenomena and sometimes laughter. As its fellow anesthetic agent and NMDA-receptor antagonist, ketamine, NO is being studied for its possible therapeutic profile in treatment resistant major depression (TRMD).

Objectives: TRMD is a serious illness, that urges for effective alternative treatments. In that regard, we explored the recent studies conducted in these patients, using NO in different dosages when compared to placebo.

Methods: The authors revised the published literature about this topic, selecting relevant articles with the topic words: “Depression”, “Treatment Resistant Major Depression” and “Nitrous Oxide” in scientific data base.

Results: Since 2018, at least two randomized clinical trials have demonstrated that NO has considerable antidepressant effects in TRMD, when compared to placebo. Investigators noted that these positive effects were maintained at least for two weeks after a single 1-hour inhalation. In a more recent study, scientists compared different NO concentrations (25% vs. 50%) concluding that the 25% concentration had similar efficacy with a lower risk of adverse effects.

Conclusions: There appears to be encouraging results when treating patients with TRMD with NO in a 25% concentration. None-theless, there is need for further investigation, namely through studies that compare NO with other valid TRMD treatments and not only versus placebo.

Disclosure: No significant relationships.

Keywords: Depression; Treatment Resistant Major Depression; Nitrous Oxide

EPV1160

Rare occurrence of amenorrhea associated with olanzapine : a case report

A. Khivsara*, D. Goya and N. Nebhinani

All India Institute of Medical Sciences, Jodhpur, Psychiatry, Jodhpur, India

*Corresponding author.
doi: 10.1192/j.eurpsy.2022.1848